128 related articles for article (PubMed ID: 12859618)
1. Melanin inhibits cytotoxic effects of doxorubicin and daunorubicin in MOLT 4 cells.
Svensson SP; Lindgren S; Powell W; Green H
Pigment Cell Res; 2003 Aug; 16(4):351-4. PubMed ID: 12859618
[TBL] [Abstract][Full Text] [Related]
2. Melanin potentiates daunorubicin-induced inhibition of collagen biosynthesis in human skin fibroblasts.
Surazyński A; Pałka J; Wrześniok D; Buszman E; Kaczmarczyk P
Eur J Pharmacol; 2001 May; 419(2-3):139-45. PubMed ID: 11426835
[TBL] [Abstract][Full Text] [Related]
3. The mechanism for anthracycline-induced inhibition of collagen biosynthesis.
Muszyńska A; Wolczyński S; Pałka J
Eur J Pharmacol; 2001 Jan; 411(1-2):17-25. PubMed ID: 11137854
[TBL] [Abstract][Full Text] [Related]
4. Affinity of ocular acid-insoluble melanin for drugs in vitro.
Tsuchiya M; Hayasaka S; Mizuno K
Invest Ophthalmol Vis Sci; 1987 May; 28(5):822-5. PubMed ID: 3570692
[TBL] [Abstract][Full Text] [Related]
5. Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs.
Blagosklonny MV; Neckers LM
Anticancer Drugs; 1994 Aug; 5(4):437-42. PubMed ID: 7949248
[TBL] [Abstract][Full Text] [Related]
6. Influence of ICRF-159 or ICRF-186 on cytotoxicity of daunorubicin and doxorubicin.
Supino R
Tumori; 1984 Apr; 70(2):121-6. PubMed ID: 6730012
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin.
Minderman H; Linssen P; Wessels J; Haanen C
Anticancer Res; 1993; 13(4):1161-5. PubMed ID: 8352539
[TBL] [Abstract][Full Text] [Related]
8. DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.
Schneider YJ; Baurain R; Zenebergh A; Trouet A
Cancer Chemother Pharmacol; 1979; 2(1):7-10. PubMed ID: 498422
[TBL] [Abstract][Full Text] [Related]
9. Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.
Deprez-De Campeneere D; Baurain R; Huybrechts M; Trouet A
Cancer Chemother Pharmacol; 1979; 2(1):25-30. PubMed ID: 498415
[TBL] [Abstract][Full Text] [Related]
10. DNA-binding characteristics of aclarubicin as compared with daunorubicin and doxorubicin.
Ando S; Kamiya K; Yoshimura T; Tsutani H; Ueda T; Uchida M; Nakamura T; Uchino H
Anticancer Res; 1988; 8(3):409-15. PubMed ID: 3164610
[TBL] [Abstract][Full Text] [Related]
11. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells.
Kuffel MJ; Ames MM
Cancer Chemother Pharmacol; 1995; 36(3):223-6. PubMed ID: 7781142
[TBL] [Abstract][Full Text] [Related]
12. Novel peptide conjugates for tumor-specific chemotherapy.
Langer M; Kratz F; Rothen-Rutishauser B; Wunderli-Allenspach H; Beck-Sickinger AG
J Med Chem; 2001 Apr; 44(9):1341-8. PubMed ID: 11311056
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of in vitro α-1 adrenergic receptor antagonist binding capacity to biologic melanin using tandem mass spectrometry.
Gaynes JS; Micic C; Gaynes BI; Borgia JA
Curr Eye Res; 2013 Dec; 38(12):1214-20. PubMed ID: 24047464
[TBL] [Abstract][Full Text] [Related]
14. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
16. Anthracyclines, proteasome activity and multi-drug-resistance.
Fekete MR; McBride WH; Pajonk F
BMC Cancer; 2005 Sep; 5():114. PubMed ID: 16159384
[TBL] [Abstract][Full Text] [Related]
17. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
Brooks TA; O'Loughlin KL; Minderman H; Bundy BN; Ford LA; Vredenburg MR; Bernacki RJ; Priebe W; Baer MR
Invest New Drugs; 2007 Apr; 25(2):115-22. PubMed ID: 17072745
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin- and daunorubicin-induced energy deprivation and nucleotide degradation in isolated cardiomyocytes.
Vidal RF; Eksborg S; Sundberg M; Carlberg M; Elfsson B; Andersson BS
Toxicology; 1996 Nov; 114(1):1-10. PubMed ID: 8931755
[TBL] [Abstract][Full Text] [Related]
19. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
[TBL] [Abstract][Full Text] [Related]
20. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
